EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Intranasal dexmedetomidine versus midazolam for procedural sedation in children: a systematic review and metaanalysis of randomized controlled trials

Ahmad M.Alridahie, Saleh K.Almasoud, Ammar K.Alhajjaj, Bassam K. Alkhalifah, Abdulrhman N.Aldubayyan

Annals of Middle Eastern Medicine · 18.08.2026 · 2 (3) · 290-301

DOI: 10.24911/amem.15-2953 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Annals of Middle Eastern Medicine, online erschienen am 15.08.2026. Verfasst von Ahmad M.Alridahie und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Procedural sedation in children remains a complex clinical challenge. Midazolam has served as the conventional standard, yet intranasal dexmedetomidine has emerged as an attractive alternative offering potential advantages regarding respiratory safety alongside improved behavioral recovery.

Objectives

To systematically review and meta-analyze the evidence from randomized controlled trials comparing the efficacy and safety of intranasal dexmedetomidine versus midazolam for procedural sedation in children aged 0-18 years.

Methods

Adhering strictly to PRISMA guidelines, a systematic search of major databases identified relevant randomized controlled trials comparing these agents. Two independent reviewers selected eligible studies, extracted data, and conducted formal risk of bias assessments. Meta-analytic data pooling utilized random-effects models.

Results

Eight trials encompassing 716 children were included. Primary endpoints proved not statistically significant: sedation onset trended faster towards midazolam (SMD=1.22; I²=96.7%), whereas satisfactory sedation trended favorably toward dexmedetomidine (RR=1.23; I²=78.4%). Importantly, dexmedetomidine significantly reduced postoperative anxiety (MD=-0.81; I²=0%), emergence delirium (RR=0.31; I²=0%), and emergence agitation (RR=0.36; I²=0%) without prolonging awakening time (MD=0.30; I²=0%). Narrative synthesis indicated fewer respiratory adverse events with dexmedetomidine.

Conclusion

Primary efficacy outcomes demonstrated statistically insignificant differences, although robust evidence indicates intranasal dexmedetomidine is highly superior for pediatric behavioral recovery. Dexmedetomidine effectively minimizes emergence delirium, agitation, and anxiety without inappropriately prolonging baseline awakening times, while demonstrating a safer perioperative respiratory profile. Midazolam maintains a practical edge strictly for rapid onset. Current evidence remains heavily limited by small sample sizes and substantial clinical heterogeneity. Well-powered multicenter trials utilizing standardized outcomes are urgently needed to fully resolve clinical dosing protocols today.

Zitieren

APA

M.Alridahie, A., K.Almasoud, S., K.Alhajjaj, A., Alkhalifah, B. K., & N.Aldubayyan, A. (2026). Intranasal dexmedetomidine versus midazolam for procedural sedation in children: a systematic review and metaanalysis of randomized controlled trials. Annals of Middle Eastern Medicine, 2(3), 290-301. https://doi.org/10.24911/amem.15-2953

Vancouver

M.Alridahie A, K.Almasoud S, K.Alhajjaj A, Alkhalifah BK, N.Aldubayyan A. Intranasal dexmedetomidine versus midazolam for procedural sedation in children: a systematic review and metaanalysis of randomized controlled trials. Annals of Middle Eastern Medicine. 2026;2(3):290-301. doi:10.24911/amem.15-2953

BibTeX
@article{MAlridahie2026,
  author = {M.Alridahie, Ahmad and K.Almasoud, Saleh and K.Alhajjaj, Ammar and Alkhalifah, Bassam K. and N.Aldubayyan, Abdulrhman},
  title = {Intranasal dexmedetomidine versus midazolam for procedural sedation in children: a systematic review and metaanalysis of randomized controlled trials},
  journal = {Annals of Middle Eastern Medicine},
  year = {2026},
  volume = {2},
  number = {3},
  pages = {290--301},
  doi = {10.24911/amem.15-2953}
}
Kostenlos starten →